Metastatic Hormone Refractory Prostate Cancer Recruiting Phase 3 Trials for Abiraterone (DB05812)

Also known as: Metastatic hormone refractory Prostate cancer / Metastatic Prostate cancer / Prostate cancer metastatic / Metastatic Prostate Carcinoma / Carcinoma of the prostate metastatic / Prostatic cancer metastatic

IndicationStatusPhase
DBCOND0036371 (Metastatic Hormone Refractory Prostate Cancer)Recruiting3
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT04446117Study of Cabozantinib in Combination With Atezolizumab Versus Second NHT in Subjects With mCRPCTreatment
NCT03748641A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate CancerTreatment